Traditionally, cardiotoxicity due to BC treatment, particularly anthracycline-based cancer chemotherapy (ACC), has been attributed to cardiomyocyte damage and death, with amino-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity troponins (hs-Tn) as the most commonly proposed biomarkers to detect cardiotoxicity [2,5,6]. The gene discussed is NPPB; the disease is cancer.